Use of Biologics in Pouchitis
- 1 September 2015
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Clinical Gastroenterology
- Vol. 49 (8), 647-654
- https://doi.org/10.1097/mcg.0000000000000367
Abstract
Data about the effectiveness of biologics, including anti-tumor necrosis factor (TNF) therapy and anti-integrin strategies, in antibiotic refractory pouchitis or Crohn’s disease–associated pouch complications are sparse. We performed a systematic review of the literature in Medline and Web of Science. All English language publications and meeting abstracts describing patients with pouchitis treated with anti-TNF or anti-integrin therapies were included. We identified a total of 17 papers and 2 abstracts, most of these retrospective case series, including a total of 192 patients treated either with infliximab (n=140) or adalimumab (n=52). No reports were found for anti-integrin therapies or other anti-TNF agents such as certolizumab pegol or golimumab. Because of the heterogeneity of the studies, small numbers of patients, differing cotreatments, and subjective outcome definitions, the exact efficacy of these biological therapies cannot be assessed in a combined fashion. Overall infliximab appears to have good clinical effectiveness in selected patients achieving up to 80% short-term and around 50% long-term response, whereas the few data available for adalimumab are not sufficient to draw valid conclusions. Larger prospectively collected multicenter data with clearly defined inclusion criteria and outcomes are necessary to better define the clinical value of anti-TNF therapy in patients with antibiotic refractory pouchitis or Crohn’s-like complications of the pouch.Keywords
This publication has 74 references indexed in Scilit:
- Ileal Pouch Anal AnastomosisAnnals of Surgery, 2013
- Successful Long-Term Use of Infliximab in Refractory Pouchitis in an AdolescentGastroenterology Research and Practice, 2010
- Modulation of Th1/Th2 Balance by Infliximab Rescues Postoperative Occurrence of Small-Intestinal Inflammation Associated with Ulcerative ColitisDigestive Diseases and Sciences, 2009
- An Assessment of Bacterial Dysbiosis in Pouchitis Using Terminal Restriction Fragment Length Polymorphisms of 16S Ribosomal DNA From Pouch Effluent MicrobiotaDiseases of the Colon & Rectum, 2009
- Long-Term Outcomes With Ileal Pouch-Anal Anastomosis and Crohn's DiseaseAnnals of Surgery, 2008
- Results at up to 20 years after ileal pouch–anal anastomosis for chronic ulcerative colitisBritish Journal of Surgery, 2007
- Double-blind crossover trial of metronidazole versus placebo in chronic unremitting pouchitisDigestive Diseases and Sciences, 1994
- Pouchitis After Ileal Pouch-Anal Anastomosis: A Pouchitis Disease Activity IndexMayo Clinic Proceedings, 1994
- Ciprofloxacin-Induced VasculitisThe New England Journal of Medicine, 1989
- Topical Administration of 5-Aminosalicylic Acid: A Therapeutic Proposal for the Treatment of PouchitisThe New England Journal of Medicine, 1989